CILNIDIPINE

THE NEXT SHARE SHIFT WILL BE WON AT THE REVIEW YOUR BRAND MAKES HAPPEN

For leaders defending default status, challengers displacing habit, and selective-share brands owning one clinic gap.

CILNIDIPINE

MOLECULE-WIDE CIRCULATION

This note is shared with leadership teams of major competing cilnidipine brands in India. The same workflow opportunity is open to direct competitors.

After 20+ years of antihypertensive brand-reminder marketing, another reminder is a weak answer to an unfinished patient journey.

YOUR POSITION	THE COMPETITIVE JOB
LEADER Defend default	Turn prescribing strength into the clinic's routine for reliable BP measurement, tolerability review and continuity.
CHALLENGER Displace habit	Make the doctor compare completed reviews and usable BP records alongside familiar molecule claims.
SELECTIVE SHARE Capture one wedge	Own one dense cluster where the first review, a tolerability concern or the next refill repeatedly gets lost.

The strategic territory: measurement-to-review continuity after the clinician has chosen cilnidipine. The clinic owns care. The competing brand earns HCP relevance by making that care easier to execute.

STRATEGIC CHOICE

OWN THE REVIEW THAT MAKES THE PRESCRIPTION ASSESSABLE

Cilnidipine's commercial value is exposed when the next clinical decision rests on unreliable readings, an unreported ankle-swelling concern or a refill gap. A reminder can repeat the brand. A useful clinic routine can make the prescription assessable.

CONVENTIONAL CALL	MOLECULE-WIDE WORKFLOW
Repeat L/N-type pharmacology	Help the clinic assemble a reliable BP and tolerability record.
Treat the prescription as conversion	Treat a completed, documented review as the first closed loop.
Repeat "better tolerability"	Make every concern easy to disclose without promising that edema cannot occur.
Promote each combination separately	Reconcile the revised prescription and prevent duplicate or outdated instructions.
Count reminders and scans	Count usable records, completed reviews, safe re-entry and continuity.

ONE ARCHITECTURE WITH MEDICINE-SPECIFIC BRANCHES

The BP-control foundation is shared with other antihypertensives. Cilnidipine earns a distinct emphasis through CCB tolerability, clinician-led switches, the quality of the first response review and continuity through combination changes. That is a defensible operational focus; it is not a claim of unique clinical benefit.

A brand does not own a patient or a clinical decision. It can become the HCP's most useful partner in completing the review.

Clinical basis: hypertension guidance and Indian product information [8–13]. Commercial advantage is a hypothesis to test, not an established causal effect.

CATEGORY PROVOCATION

FAMILIARITY CREATES A DEFAULT AND LEAVES AN OPENING

The familiar cilnidipine conversation is easy to reproduce: BP lowering, L/N-type action, tolerability and combination breadth. Familiarity helps the incumbent. It also makes repeated claims a poor route for a challenger to change established habit.

CATEGORY HABIT	WHAT REMAINS UNRESOLVED	COMPETITIVE IMPLICATION
The molecule is selected	Will the patient return with readings the clinician can use?	Prescription reach is larger than review capability.
The patient feels well	Is treatment being taken and measured as agreed?	Silence can hide non-use and missed reviews.
Tolerability is discussed	Will swelling, dizziness or palpitations reach a clinician?	A claim without a contact route leaves the concern unmanaged.
The pack is dispensed	Does it match the current prescription and remain affordable?	Continuity can fail after a successful call.
BP remains above target	Is this technique, missed use, context or the regimen?	The next decision needs evidence, not another message.

THE CATEGORY-CONTROL THESIS

The opportunity is to establish a repeatable clinic standard before it becomes ordinary. Staff training, an adopted review format, reliable contact routes and evidence of completed reviews are harder to displace than a leave-behind. The first team earns that position only by making the service useful.

The vulnerable point is not familiarity with cilnidipine. It is the unfinished work after familiarity has already won the prescription.

These leakage mechanisms are strategic hypotheses. Their frequency in any territory must be established during baseline observation; no national leakage rate is assumed.

INDIA MARKET EVIDENCE

LARGE INCUMBENT SIGNALS AND A CROWDED COMBINATION MARKET

Public evidence establishes commercial scale and competition. It does not establish a complete September 2026 national cilnidipine leaderboard. Every number below retains its period, denominator and source type.

PUBLIC SIGNAL	VERIFIED FACT	USE AND LIMIT
Hypertension need [1]	WHO's 2025 India profile estimates 210.2 million adults aged 30–79 with hypertension in 2024; 17% controlled.	Disease burden, not cilnidipine use or a sales forecast.
Cilacar scale [2]	JB reports INR520 crore Cilacar value sales and INR908 crore for the Cilacar franchise, IQVIA MAT Dec 2025.	Brand and broader franchise are separate measures. Neither is total molecule revenue.
Dated leadership proxy [4]	JB FY25 reports Cilacar #1 in its covered market with 55% share, MAT Mar 2025.	Company-reported, dated covered-market claim; not a fresh independent rank audit.
Challenger presence [3]	Alembic's Q1 FY27 Rx-driven table lists Cetanil at rank 2 and 6.9%, source IQVIA MAT Jun 2026.	Retain the company table's molecule-group definition. Do not compare this percentage directly with JB's older value-share claim.
Combination crowding [5]	NPPA's April 2024 dataset for cilnidipine 10 mg + telmisartan 40 mg + chlorthalidone 12.5 mg lists 30 pack rows: 28 distinct brand labels.	Own count from one dated strength-specific worksheet, not all active cilnidipine brands. It lists 13 companies at ⩾1% and total MAT of INR95.44 crore.

The evidence supports a large incumbent and a long competitive tail. “Crowded” does not mean that share is evenly fragmented.

MAT = moving annual total. Company-reported market sales are not the manufacturer’s recognised revenue. The NPPA figure is a pricing-workbook market value. Do not add these overlapping, differently dated universes.

COMPETITION AND PRESCRIBERS

DEFINE THE MARKET BEFORE CHOOSING THE ATTACK

Keep cilnidipine monotherapy, each exact combination and the total cilnidipine-containing franchise in separate views. A brand can lead one and trail another. Company ownership must also be current.

QUESTION	PUBLIC EVIDENCE	DECISION RULE
Who competes?	Cilacar and Cetanil are disclosed large-brand signals. Torcilin has current Indian PI. NPPA names multiple combination families, including Cetanil Trio, Cilacar TC, Dilnip Trio, Nexovas TC, Telmikind Trio and Telplus Trio. [2,3,5,13]	Examples establish presence, not an exhaustive current ranking.
How many independent groups?	Torrent's FY26 disclosure includes JB acquisition effects from 21 January 2026. [6]	Do not count Torrent and JB as independent rival groups. Brand labels, marketers and parent groups are different counts.
How prevalent is prescribing?	The five-centre RECORD registry, n=2,000, reported cilnidipine in 17 of 689 historical monotherapy records at initial diagnosis (2.5%). [7]	A bounded historical registry proxy, not national current prescription prevalence.
Which specialties lead?	Current national specialty shares were not publicly established. Clinical workflow and Indian evidence support physicians/internal medicine and cardiologists; diabetologists and nephrologists are relevant for selected comorbidity cohorts. [7,11,19]	This is a deployment-priority inference, not a ranked Rx-volume table. Include family/general practice where continuity capacity is real.

THE COMMON DECISION DATASET

Before assigning current rank, choosing a district or forecasting share, obtain one licensed IQVIA/PharmaTrac-equivalent cut: MAT and recent quarters, value and units, mono versus exact FDC, active brands and SKUs, parent ownership, geography, price band, new/repeat prescriptions and specialty split. Document the dataset's coverage and deduplication rules.

The note can circulate with these labelled public proxies. Any added current national ranking, market-size or specialty-share assertion requires the corresponding auditable dataset.

EMBEDDED CLINICAL ENGINE

RESPONSIBLE USE IS THE OPERATING SPINE

Entry follows clinician-confirmed hypertension and clinician selection of cilnidipine. Diagnosis and drug choice are upstream clinical tasks. They are not patient acquisition features of this service.

NON-NEGOTIABLE	WORKFLOW CONSEQUENCE
Measurement before judgement [8,9,12]	Teach technique, record the measurement setting and use the clinic's schedule. No diagnosis or traffic-light treatment advice from isolated readings.
Review after initiation or change [8,10]	Book a clinician-set review, typically within 2–4 weeks for this pathway. WHO suggests monthly review until target; earlier contact is needed for concerns. This cadence is not a cilnidipine-specific efficacy claim.
Tolerability remains uncertain [13,15]	Ask neutrally about edema, dizziness, headache and palpitations. Record timing and impact; the clinician assesses cause and treatment.
The actual product governs [13,14]	Use the current India PI for the selected brand, strength and formulation. Monotherapy instructions cannot be copied across all combinations.
Special populations need clinician review [9,13,19]	Older age, falls, pregnancy plans, breastfeeding, hepatic disease and CKD need appropriate clinical assessment. No generic high-risk self-management pathway.
Every treatment decision stays clinical	No molecule recommendation, dose selection, start/stop/switch message, automated titration or reassurance that a concerning symptom is harmless.

Base population: consenting adults under an identified treating clinic. Pregnancy, paediatric use and acute unstable illness are outside the routine pathway.

BP targets differ across guidelines and patient groups. The clinician records the individual target and whether it applies to home or clinic readings; the service does not choose or convert it.

EVIDENCE AND CLAIM DISCIPLINE

TOLERABILITY IS A REVIEW OPPORTUNITY RATHER THAN A GUARANTEE

The clinical case for the workflow is stronger than a sweeping superiority campaign. Keep guideline recommendations, comparative trials, surrogate endpoints and mechanism separate.

EVIDENCE	WHAT IT SUPPORTS	WHAT IT DOES NOT ESTABLISH
CCB role and Indian consensus [8–11]	Guidelines support CCB-based BP treatment in appropriate patients. InSH 2025 discusses cilnidipine and CCB adverse-effect monitoring.	A universal preference for cilnidipine over other CCBs or a licence to extend approved indications.
Indian randomised open-label study [15]	100 adults, 12 weeks: similar BP reduction; fewer reported edema/palpitations with cilnidipine than amlodipine.	No edema, universal tolerability superiority or a reduction in cardiovascular events.
Switch series [18]	27 selected patients with amlodipine-associated edema improved after a clinician-led switch in a short prospective study.	A controlled comparison, a patient-directed switch rule or certainty about another patient's swelling.
CARTER [16]	339 RAS-inhibitor-treated patients with CKD; one-year open-label randomised comparison found greater proteinuria reduction with cilnidipine.	Proof of prevention of kidney failure or benefit in every diabetes/CKD subgroup.
SAKURA [17]	365 patients with diabetes and microalbuminuria on RAS inhibition; no greater albuminuria benefit versus amlodipine over 12 months.	A consistent renal-superiority claim across populations.
L/N-type action [13]	A pharmacological explanation for scientific discussion.	A clinical diagnosis of "sympathetic hypertension" or proven mortality, stroke or renal-outcome superiority.

No "edema-free", "kidney-protective for everyone" or "no reflex tachycardia" promise. Better capture of concerns is a service claim that can actually be tested.

CKD education must retain guideline-directed kidney-protective care. Cilnidipine does not replace indicated ACEi/ARB or other evidence-based treatment. [19]

CENTRAL COMMERCIAL AND BEHAVIOURAL DRIFT

THE PRESCRIPTION CAN SURVIVE WHILE CONTINUITY FAILS

Leakage is not only a lost brand. It is also a poor reading, a concern that never reaches the clinic, or a regimen change that leaves the patient following an old plan. Commercial recovery starts with making those events visible to the right person.

LEAKAGE	PATIENT OR CLINIC FAILURE	COMMERCIAL EXPOSURE
Measurement noise	Wrong cuff, timing or posture makes the BP record hard to interpret.	The product is judged on unreliable evidence.
Asymptomatic drift	Feeling well removes the perceived reason to measure, take medicine or attend.	Use and repeat purchase become irregular.
Unspoken tolerability	Swelling or dizziness is tolerated silently or followed by self-change.	Trust erodes before the brand team sees a signal.
Missed first review	The record, appointment and concerns never meet in one consultation.	An initial choice fails to become a durable clinic routine.
Uncontrolled BP ambiguity	Technique, use, interactions and regimen fit remain unresolved.	The next choice becomes harder to explain and support.
Combination confusion	The new prescription is added to an old pack without reconciliation.	Franchise breadth creates confusion instead of continuity.
Supply and affordability	Unavailable stock, pack changes or cost interrupt access.	Prescription intent is lost downstream.
Lost re-entry	The patient disappears after a gap, adverse concern or treatment change.	A recoverable relationship becomes a silent exit.

Commercial consequences are hypotheses to validate. An appropriate clinician-led switch is a successful care event even when it reduces a brand's sales.



Leadership Edition

MOMENTS THAT MATTER

NINE MOMENTS THAT CAN CLOSE OR BREAK THE LOOP

Diagnosis confirmation is an upstream clinic gate. The service activates only after cilnidipine selection and supports the following moments without choosing treatment.

MOMENT	CLINIC TASK	PATIENT FRICTION	HCP-LAYER OPPORTUNITY
1 Handover	Confirm current prescription, measurement plan and review date.	Forgotten instructions; silent disease feels unimportant.	Make the selected plan easy to follow.
2 Home measurement	Check device, cuff and teach-back; arrange clinic readings if needed.	No device, wrong technique or selective logging.	Make the first BP record usable.
3 Days 3–7	Provide an early access and tolerability contact route.	Swelling, dizziness or questions remain unspoken.	Demonstrate responsible follow-through.
4 Weeks 2–4	Review BP, use, tolerability and all medicines.	No appointment or incomplete record.	Earn relevance through a completed review.
5 BP above plan	Reassess technique, use and context; clinician chooses action.	Blame or self-escalation.	Support review quality rather than a reflex switch.
6 Regimen change	Reconcile old and new instructions, including each FDC component.	Duplication, wrong strength or old-pack use.	Keep the clinical handover intact.
7 Refill and pack	Resolve cost, availability and prescription mismatch.	Missed supply or unexplained substitution.	Reduce avoidable loss of prescription intent.
8 New concern	Assess falls, hypotensive symptoms, reproductive or comorbidity change.	Waiting for the routine review despite a concern.	Make timely clinical re-entry reliable.
9 Longer-term return	Set the next review and welcome return after a gap.	Feeling cured, embarrassment or lost contact.	Build repeat clinic use without pressuring medicine choice.

Cadence and clinical boundaries: [8–14,19,23]. The commercial column describes brand-team strategy, never patient-facing persuasion.

INTEGRATED CLINIC SERVICE

BP CONTROL AND CONTINUITY PATHWAY

A generic, clinic-branded and brand-neutral pathway that turns home information into a clinician-reviewed plan. For cilnidipine-selected journeys, the distinctive emphasis is reliable BP plus tolerability and prescription reconciliation.

CLINIC SELECTS → PATIENT MEASURES AND NOTES CONCERNS → CLINIC REVIEWS → PATIENT RECEIVES THE UPDATED PLAN → CONTINUITY AND RE-ENTRY

LAYER	OWNER AND FUNCTION	VISIBLE BRANDING
Clinical core	An independent Academy/faculty panel reviews evidence, scripts, forms, translations, escalation language and updates.	Clinical education identity only; Academy review is not product endorsement.
Patient shell	Treating clinic supplies its identity, contact route, hours, individual plan and next review date.	Clinic identity; no medicine promotion or sponsor logo.
Review and response	Clinic staff receive messages through agreed channels, prepare the record and document clinician decisions.	Clinic identity; no rep access to clinical records.
HCP and field layer	Approved product information, adoption support, supply issue resolution and aggregate service reporting after selection.	Brand presence only in permitted HCP/field materials.

ONE MINIMUM SERVICE

A plan card, a short technique guide, a concern/contact route and a one-page review record. Access by a simple link, QR or paper; no mandatory app or patient account. Phone or staff assistance must remain available to patients who cannot use the digital route.

“Academy-backed” is the governance architecture to establish. Do not label the pathway certified, accredited or endorsed until the relevant body has formally authorised that claim.

Service access continues after a clinician changes the medicine. Support cannot be conditional on buying a sponsor brand.

MODULES AND CADENCE

BUILD A USABLE RECORD BEFORE THE FIRST REVIEW

These are operating defaults for an approved clinic pathway. The clinician can bring a review forward or change the measurement schedule. A concerning symptom is never held for a scheduled check.

MODULE AND TIME	PATIENT ACTION	CLINIC OUTPUT
1 Plan handover Day 0	Receive clinic contact/hours, the clinician's instructions, measurement setting and next review date. Teach back where to ask for help.	A named reviewing clinician and booked date; consent and preferred language recorded in the clinic.
2 Technique support Day 0–3	Check a validated upper-arm device and correct cuff. Demonstrate the method once. If home measurement is impractical, use the clinic's alternative.	Technique confidence and device/access problems visible before the readings are judged.
3 Early-use check Days 3–7	Record access problems, missed use and any new swelling, dizziness, headache or palpitations. Contact the clinic through its normal route.	A concise concern note, routed under the clinic's response standard.
4 Review preparation Before the agreed visit	Bring the BP record, current medicine list/packs, use history, concerns and ordered test results if relevant.	One record ready for a typical 2–4-week clinician review.

TECHNIQUE THAT PRODUCES INTERPRETABLE INFORMATION

Use a validated upper-arm cuff of the right size. Avoid exercise, smoking and caffeine for 30 minutes; empty the bladder, sit quietly for 5 minutes, support the back and arm, keep feet flat and avoid talking. Take paired readings about one minute apart. Follow the clinic's agreed morning/evening schedule and preserve all readings. [12]

For diagnostic HBPM, NICE uses at least 4 days, ideally 7, with day 1 excluded from the average. A treated patient's review schedule is clinician-set; the service does not silently apply a diagnostic rule to every log. [9]

No device purchase is required for enrolment. Do not penalise patients without a monitor or reward staff for branded device distribution.

REVIEW AND CONTINUITY MODULES

MAKE EVERY CONCERN END IN A VISIBLE NEXT STEP

The service cannot promise control. It can make the next decision easier to reach and record whether it occurred. A one-way reminder with no clinic response route is not this pathway.

MODULE	CADENCE	CLOSURE
5 BP and tolerability review	Typically weeks 2–4 after initiation or change; earlier if the clinician directs.	Clinician assesses readings, missed use, symptoms and medicines; documents a plan and next date.
6 Not-at-target review	Event-triggered after the clinic assesses the record.	Technique/adherence/context are considered; any titration, add-on, FDC, investigation or referral is clinician-led.
7 Refill and reconciliation	One neutral prompt before the patient's expected supply ends; timing reflects the actual prescription.	Availability, cost or unfamiliar pack is clarified with the clinic/pharmacist. No forced brand purchase.
8 Plan-change handover	Whenever the clinician changes treatment.	Current instructions are reconciled; old/new pack ambiguity is resolved by a qualified professional.
9 Return after a gap	At a missed review or patient-requested return; use limited, consented outreach.	Patient reconnects with the clinic. No instruction to restart an old prescription.

THE LONGER CLINICAL CLOCK

WHO suggests monthly follow-up after a medicine is started or changed until the target is reached, then every 3–6 months when controlled. These are conditional recommendations; the clinic adapts timing to the person. [10]

Completed review means the clinician saw the information and recorded the next plan. A delivered message, uploaded log or booked visit is not closure.

The day 3–7 check and refill prompts are proposed service design. They are not guideline-mandated cilnidipine monitoring intervals.

SAFETY AND ESCALATION

A SAFETY CONCERN NEEDS AN ACTIONABLE ROUTE TO CARE

Use clinician-approved static safety instructions and clear contact routes. The patient tool does not diagnose an emergency, assign a risk score, interpret drug causality or recommend treatment changes.

SITUATION	PATIENT-FACING DIRECTION	CLINIC RESPONSIBILITY
Emergency symptoms	For chest pain, severe breathlessness, collapse, new weakness, speech difficulty, sudden visual loss or severe allergic symptoms, seek emergency care now. Do not wait for a reply or a BP reading.	Publish a locally verified emergency route. The service must not imply continuous monitoring.
Very high home BP	If systolic is above 180 OR diastolic above 120 mmHg and there are no emergency symptoms, repeat after at least one minute; if still that high, contact a clinician urgently. Symptoms override waiting. [23]	Approve wording and local fallback. No self-dosing advice and no automated “safe to wait” message.
Swelling or persistent discomfort	New or worsening ankle swelling, troublesome headache or palpitations should be reported. Sudden one-sided painful swelling or associated breathlessness needs urgent assessment.	Assess alternative causes and urgency; never assume all swelling is a harmless CCB effect.
Dizziness, falls or low-BP symptoms	Contact the clinic promptly for lightheadedness, near-fainting or a fall; collapse or severe symptoms require urgent care. Avoid driving while dizzy. [13]	Assess standing BP when indicated, medicines, hydration and falls risk; set any individual low-reading contact threshold.
Pregnancy or breastfeeding	Contact the treating clinician promptly if pregnant, planning pregnancy or breastfeeding. Do not wait for the routine review.	Current PI and specialist judgement govern. Telmisartan-containing products have additional fetal-risk warnings. [13,14]

A static safety card does not replace examination. Outside clinic hours, the patient sees the approved urgent-care alternative. A reporting form is never an emergency service.

REFILL AND REGIMEN TRANSITIONS

PROTECT PRESCRIPTION INTENT WITHOUT TRAPPING THE PATIENT

Exact-brand continuity is a downstream commercial measure, not a patient-care instruction. The patient-facing task is to verify that the dispensed medicine matches the current prescription and to resolve differences with a qualified professional.

MOMENT	NEUTRAL SUPPORT	BOUNDARY
Unfamiliar pack	"If the pack or instructions look different, ask your pharmacist or clinic to check them against your current prescription."	No claim that another brand is inferior. No rep-mediated clinical substitution advice.
Supply or cost difficulty	"Tell the clinic or pharmacist before your supply runs out if cost or availability may cause a gap."	The clinician/pharmacist resolves the practical option. No brand-linked incentive.
Missed medicine	"If you missed a dose or are unsure what to do, use the instructions supplied for your medicine or ask the clinic/pharmacist."	No generic catch-up, doubling, restarting or dose-change rule.
Changed combination	Bring the latest prescription and current packs for reconciliation.	Check all components and strengths. Never assume a familiar brand suffix means the same medicine.
Return after stopping	"You can contact the clinic even if you have missed medicine or appointments. Bring the last prescription and explain what happened."	No blame and no automated instruction to resume old treatment.

MONOTHERAPY AND FDCS SHARE A SERVICE RATHER THAN A SAFETY SCRIPT

A telmisartan-containing FDC needs its ARB pregnancy and renal/potassium safeguards. A diuretic-containing FDC needs its own monitoring considerations; a beta-blocker combination has a different pulse and withdrawal context. The clinic selects the applicable branch from the exact approved product. [14,19]

A clinically appropriate change of brand, dose or molecule is successful care. Never classify it as a service failure to improve retention numbers.

DOCTOR-FACING LAYER

GIVE THE CLINICIAN A BETTER BASIS FOR THE NEXT DECISION

After cilnidipine selection, the HCP layer combines concise approved-label support with a usable patient record. The clinician retains diagnosis, patient fit, target, dosing, monitoring and every escalation choice.

CLINICAL TASK	SUPPORT AT THE POINT OF REVIEW
Patient fit and prescription	Current India PI; diagnosis/risk already assessed; reconciliation of indications, contraindications, comorbidities and other medicines.
Counselling	Neutral explanation of asymptomatic hypertension, measurement technique, medicine questions, concerns to report and the next review.
Tolerability	Timeline of edema, dizziness, headache or palpitations; impact on daily life, missed use and any urgent contact already made. No prefilled causal attribution.
BP assessment	Raw readings, dates/times, home versus clinic setting, technique/device status and missing data; no service-generated diagnosis.
Titration or add-on review	Medicine reconciliation, affordability and use history alongside BP and tolerability. All treatment options remain clinician choices.
Older patient or falls	Prompt the clinician to consider standing BP, frailty, falls, polypharmacy and individual treatment tolerance. [9,13]
Diabetes and CKD	Include clinic-ordered renal, potassium or albuminuria results when relevant. Preserve evidence-based background therapy and avoid a renal-superiority inference. [16,17,19]

THE ONE-PAGE REVIEW RECORD

Visit date and measurement setting; BP log and technique status; medicine list; missed-use/access history; concern timeline; ordered-test status; patient questions. A separate clinician-only box records assessment, plan and next date. No automated recommendation appears in the record.

Safety cues follow the selected product's current Indian PI [13,14]. The sponsor's product material and the clinic's patient record remain separate.

ACADEMY-BACKED EDUCATION

SIX MONTHS OF BETTER CLINICAL DECISIONS

A proposed independent mini-CME and case-share series supports the same clinic routine. It is not a six-month product-promotion calendar. Faculty select cases and present conflicting evidence.

MONTH	MINI-CME AND CASE	PRACTICE CHANGE	CORE AUDIENCE
1	The misleading BP log: cuff, posture and measurement setting	Use technique teach-back and preserve all readings.	Physicians, cardiologists, family/general practice
2	Swelling or dizziness after a CCB prescription	Separate disclosure, differential assessment and treatment choice.	Physicians and cardiologists
3	The first review that did not happen	Document use, tolerability and a clinician-reviewed next plan.	High-volume outpatient prescribers
4	Above-target BP despite reported adherence	Review technique, access, regimen and clinical context before intensification.	Physicians, cardiologists and diabetologists
5	Cilnidipine in a patient with CKD or diabetes	Read CARTER and SAKURA together; retain guideline-directed kidney care.	Nephrologists, diabetologists and physicians
6	Falls, combination confusion or return after a gap	Reconcile medicines and individualise review; share a de-identified pathway case.	All participating segments; geriatric focus where relevant

A COMPACT MONTHLY FORMAT

A 15-minute evidence capsule, a 10-minute case discussion, one reusable clinic aid and one anonymous practice-change check. Offer a low-bandwidth recorded version. Attendance and completion are educational measures, not prescribing commitments.

WHAT THE ACADEMY MUST OWN

Faculty independence, evidence grading, case de-identification, language review, sponsor disclosure, version control and correction. Formal certification or CPD credit requires documented authorisation. No endorsement of a brand or device is implied. [20]

Clinical foundations [8–19]. Case sharing requires appropriate consent and de-identification; the sponsor receives no patient narrative or identifiable record.

LEADER STRATEGY

TURN PRESCRIPTION LEADERSHIP INTO CLINIC INFRASTRUCTURE

The leader's danger is assuming that default prescribing already equals a defended patient journey. A competitor can enter through the work the default leaves unfinished.

LEADER MOVE	EXECUTION	WHAT TO PROVE
Defend high-value clinics	Start where existing cilnidipine use is strong but early reviews and refill reconciliation are inconsistent.	The routine is used between calls, not only during rep visits.
Standardise the first review	Make the clinic's BP/tolerability record and booked date part of usual handover.	More eligible episodes reach a documented review.
Connect the franchise	Support exact-product reconciliation across monotherapy and clinician-selected combinations.	Fewer unresolved instruction or supply mismatches.
Make concerns safe to disclose	Create a neutral route for edema, dizziness and missed medicine.	Appropriate clinical changes are recorded without retention pressure.
Protect through usefulness	Train clinic staff and maintain the standard when reps change territories.	Clinic adoption and review quality persist after the initial activation.

WHAT THE LEADER MUST RESIST

Do not turn the service into a branded adherence campaign or a device giveaway. Do not count every treatment change as leakage. A large franchise needs stronger clinical credibility precisely because it has more to defend

THE LEADER'S QUESTION:
HOW MUCH OF THE INSTALLED PRESCRIBING BASE IS PROTECTED BY A WORKING REVIEW ROUTINE RATHER THAN HABIT ALONE?



CHALLENGER STRATEGY

CHANGE WHAT THE CLINICIAN COMPARES

A challenger that repeats the incumbent's science accepts the incumbent's rules. A credible alternative is to make the next review easier to complete and more useful to the doctor.

ATTACK SEQUENCE	PRACTICAL MOVE	CREDIBILITY TEST
Find the unfinished task	Observe one cluster's first-review process before introducing the pathway.	The gap is documented, not asserted by the sales team.
Demonstrate one completed loop	Show the clinic-branded guide, patient-held record and clinician closure.	A doctor sees usable information without another dashboard.
Reduce work per review	Train the assistant to check technique and assemble the record.	Staff time and patient access remain manageable.
Connect proof to the HCP conversation	Present aggregate review-completion and access results; retain balanced product information after selection.	Service evidence is not relabelled as drug superiority.
Expand only after repeat use	Add adjacent clinics when the first cluster maintains the routine.	Commercial lift is tested with an appropriate comparator.

DO NOT OUT-REMIND THE LEADER. MAKE A COMPLETED REVIEW THE NEW BASIS OF COMPARISON.

THE CHALLENGER ARGUMENT

“When you choose cilnidipine, this pathway helps your clinic receive a better BP record, identify tolerability concerns and complete the next review. The clinical decision remains yours.”

The pathway does not solicit a switch from a competing product. Claims must be fair, substantiated and approved; service access and education cannot be contingent on prescribing. [20]

SELECTIVE SHARE AND MID TIER STRATEGY

CHOOSE ONE GAP THAT CAN BE SERVED COMPLETELY

A mid-tier brand wins by concentration. Rank wedges by observable leakage, clinic access, response capacity and local supply. All entry follows clinician selection of cilnidipine.

PRIORITY	WEDGE	WHY IT IS DEFENSIBLE	CONSTRAINT
1 Start here	New starts or clinician-led changes with missed first reviews	A clear time window and a measurable closure event; BP and tolerability belong together.	Do not turn newly diagnosed patients into a drug-recommendation funnel.
2	Refill-dropout or high-substitution clinic clusters	A practical access/reconciliation problem can be observed and resolved.	Measure local incidence first; affordability and appropriate substitutions take precedence.
3	Clinician-selected CCB switchers after tolerability concerns	Comparative and small switch studies justify careful follow-up, not certainty of benefit. [15,18]	The prescriber selects the switch and evaluates other causes of edema.
4 Case by case	Older adults with falls or dizziness concerns	Review and medicine reconciliation can improve clinical visibility.	Needs active clinician capacity and individual targets; no automatic escalation.
5 Specialist extension	Diabetes/CKD clinics with review or reconciliation gaps	The workflow supports BP review within specialist care.	No “renal-protection” acquisition claim. Retain evidence-based background therapy. [16,17,19]

RECOMMENDED OPENING WEDGE: THE FIRST 28 DAYS AFTER A CLINICIAN-SELECTED START OR CHANGE, IN ONE DENSE PHYSICIAN/CARDIOLOGY CLINIC CLUSTER.

Use CKD/diabetes as a specialist operating context only when medical governance and clinic capacity justify it. Do not choose a wedge because its disease label sounds commercially attractive.

Reject any wedge that needs off-label promotion, patient targeting by sensitive clinical data, unmanaged alerts or a national leakage estimate that has not been measured.

FIELD FORCE STORYLINE

MOVE THE CALL FROM RECALL TO A CLINIC TASK

The representative introduces an approved workflow to the HCP after molecule selection. The rep does not collect BP readings, interpret symptoms or negotiate a patient's therapy.

OLD CALL	NEW CALL
Repeat molecule mechanism and seek recall	Identify whether BP records and early reviews are routinely completed.
Leave another leaflet	Demonstrate the clinic's four-part service in a minute.
Ask for prescriptions	Agree a staff-led activation and review the clinic's adoption barriers.
Follow up only on sales	Review aggregate operating proof and separately discuss audited commercial movement.

THE 30-SECOND STORYLINE

"Doctor, once you choose cilnidipine, the next decision needs reliable BP readings, an honest account of medicine use and any tolerability concern. This clinic-branded pathway brings those together for your review. Your team shares one access point; the patient brings one record; every treatment decision stays with you."

THE FIVE-MINUTE CALL

TIME	JOB
0–1 minute	Understand one review gap; do not request patient-identifiable examples.
1–2 minutes	Show the patient shell and one clearly illustrative review record.
2–3 minutes	Explain the concern route, clinic hours, emergency fallback and data boundaries.
3–4 minutes	Confirm the staff owner, normal contact channel and next training slot.
4–5 minutes	Agree one adoption check; keep product information in its approved HCP layer.

If an adverse event is mentioned, the rep follows the company PV process promptly. Clinical care and PV reporting are separate from selling activity. [20,22]

ASSET SYSTEM AND CLINIC CAPACITY

MAKE THE PATHWAY EASIER THAN THE WORK IT REPLACES

A useful service removes repeated explanation and missing information. It still needs real staff time. Do not promise “zero clinic effort” or an unattended safety inbox.

CORE ASSET	PURPOSE	OWNER
Clinic plan and access card	Clinic contact/hours, next review, instructions and consent route	Clinic
Technique card and short video	Demonstration in the patient’s language with a paper alternative	Academy-reviewed core; clinic teaches
Early-use and concern form	Brief, neutral capture with clear direct-contact instructions	Clinic
One-page review record	BP, medicine use, tolerability, access, questions and clinician closure	Patient and clinic
Refill and pack-check card	Resolve mismatch, availability and cost without brand persuasion	Clinic/pharmacist
HCP evidence and PI pack	Evidence hierarchy, label, comorbidity boundaries and balanced comparisons	Medical/regulatory
Rep demonstration and adoption card	30-second storyline, activation steps, permitted metrics and PV route	Field training
Operating scorecard	Primary metric, response audit, staff time and equity of access	Clinic lead and independent analyst

LOW-FRICTION OPERATING ASSUMPTIONS TO TEST

Aim for a staff handover of roughly 60–90 seconds and a review-preparation step under 3 minutes per episode; these are pilot design targets, not measured savings. Provide one brief weekly aggregate tally. Avoid duplicate clinical entry and integrate with the clinic's existing record.

Before activation, name the person covering messages, the clinician receiving concerns, the response hours and the urgent fallback. If capacity is absent, use paper/self-held records and direct contact rather than an unstaffed remote-capture service.



MEASUREMENT MODEL

USE ONE PRIMARY DECISION METRIC

Primary metric: the proportion of enrolled, eligible episodes with a completed clinician review by day 28. It tests whether the pathway closes the gap it claims to address.

DAY-28 CLOSED-REVIEW RATE = episodes with a documented qualifying clinician review by day 28 ÷ all enrolled eligible episodes that have reached day 28

DEFINITION	RULE
Eligible episode	Adult, treating clinic identified, clinician has selected cilnidipine at a start or change, and consented enrolment. One index episode per patient in the pilot.
Qualifying review	Clinician documents BP assessment using an adequate home record or clinic measurement, medicine/use review, tolerability review, and next action/date.
Denominator integrity	Include missed visits and records not returned. Report withdrawals, deaths and missing outcomes separately; do not remove unsuccessful episodes to improve the rate. Respect withdrawal and lawful data retention.
Timing	Day 0 is enrolment. Record the actual review date and clinic-planned date; count early clinician review if all elements are completed. A booking or message alone does not qualify.
Clinical change	A clinician-led dose, brand or molecule change can qualify as a completed review. Exact-brand retention is not required.
Verification	Clinic records support the count; an authorised auditor checks a sample within the clinic's permitted environment. The sponsor receives aggregate results only.

THE CAUSAL CHAIN TO TEST

Clinic activation → usable BP and medicine-use information → tolerability disclosure and review/re-entry → continuity with the agreed prescription → commercial movement. Each arrow is a hypothesis. A strong result at one stage does not prove the next.

A service-engagement metric is deliberately primary. BP control and sales remain important secondary outcomes with different denominators and greater attribution risk.

CLINICAL AND COMMERCIAL SCORECARD



Keep the evidence streams separate : Measure the behaviour the service changes, then test whether commercial movement follows. Separate independent market audits from patient care records.

STAGE	SECONDARY MEASURE	INTERPRETATION
Activation	Clinics with named owner, live pathway and first eligible enrolments; eligible offers versus enrolments	Avoid counting trained or scanned clinics as active.
Measurement and use	Usable BP records / matured episodes; self-reported missed-use and access concerns	Self-report is not proof of ingestion. Include patients using clinic measurements.
Tolerability and re-entry	Concerns raised, clinic acknowledgements, unresolved cases and completed re-entry	More reported concerns may indicate better disclosure; do not reward low AE counts.
Clinical status	BP at clinician-set target, with setting and denominator fixed; review treatment changes separately	Report among all matured episodes and those measured. No causal BP-lowering or outcome claim from a short uncontrolled pilot.
Exact-brand continuity	Verified expected refill events with the prescribed exact brand supplied / all expected refill events in an authorised audit	Separate clinically changed plans, affordability substitutions, stock-outs and unknown status. No patient reward for brand retention.
Commercial movement	Independent territory/clinic-panel value or unit share, new/repeat signals and FDC migration	Use a predefined market basket and comparator. Correct for price, stock, promotion and seasonal effects.



ECONOMICS BEFORE NATIONAL SCALE

Calculate cost per completed review and incremental completed review versus comparator. For commercial assessment, use attributable incremental contribution after programme and supply costs, not gross sales. Set the minimum worthwhile lift from local economics before launch; no ROI is assumed here.

Sponsor reporting must not link individual BP, symptoms, prescription details or adherence to sales. Any dispensing audit requires its own lawful purpose, permissions and de-identification safeguards.

GOVERNANCE AND GUARDRAILS

COMMERCIAL URGENCY CANNOT OVERRULE CLINICAL CONTROL

Medical, regulatory, legal, PV and clinic operations approve the final deployed configuration. The pathway architecture below is designed for review; it does not confer approval or certification.

CONTROL	OPERATING RULE
Patient neutrality	Clinic-branded shell; no sponsor/product promotion, brand recommendation or medicine-linked incentive. Care continues after a treatment change.
Approved-label layer	HCP product material only after cilnidipine selection. Current India PI for each SKU controls indications, counselling and safety; retain balanced evidence. [13,14,20]
Treatment and hypotension	No automated target, diagnosis, dosing or start/stop/switch advice. Clinic handles hypotension, falls, swelling and other concerns; emergency instructions remain visible.
Reproductive safety	Routine pathway excludes pregnancy. Planning, pregnancy or breastfeeding prompts timely clinician contact; combination-specific fetal warnings must be retained. [13,14]
Pharmacovigilance	A medical/PV lead defines collection, routing, staff training, reconciliation and applicable reporting timelines. Suspected events are not filtered by causality or commercial relevance. [22]
Consent and minimisation	Explain purpose, access, sharing, retention and withdrawal in the patient's language. Collect only what the clinic needs. Design against applicable Indian privacy requirements and DPDP's phased implementation. [21]
Data separation	Clinic clinical records and necessary PV cases have controlled access and retention. Sponsor reporting is non-identifiable aggregate with small-cell suppression; no rep clinical dashboard.
Operational truth	Publish response hours and fallback; log ownership and closure. Disable collection if the clinic cannot respond. No claim of continuous monitoring.

Prefer patient-held or clinic-held records. A "no data retained" claim may be used only if technically true; clinical records and legally necessary PV retention must be disclosed separately. Accreditation, ethics review and regulatory classification depend on the actual implementation.

FIRST-MOVER PILOT

CONFIGURE THEN ACTIVATE THEN PROVE

A 90-day pilot should test one complete clinical loop in a defined competitive setting. It should not attempt to prove national market leadership or long-term cardiovascular benefit.

PHASE	OPERATING WORK	EXIT EVIDENCE
Days 1–15 CONFIGURE	Choose one geography and exact market basket. Establish baseline review completion, consent, clinic capacity, PI branches, safety routes, faculty oversight and evaluation design.	Approved materials; tested routes; named owners; locked metric definitions and baseline/comparator plan.
Days 16–45 ACTIVATE	Train clinic staff, launch the minimal service and enrol consecutive eligible patients. Review burden, access and first concerns weekly.	Actual use, usable records, functioning response routes and no unresolved safety-process failures.
Days 46–90 PROVE	Maintain the routine, close reviews and audit a sample. Stop enrolment in the day-28 evaluation cohort by day 62 so every primary episode matures by day 90.	Primary metric with denominators and uncertainty; safety/capacity results; early commercial and economic signals.

DIFFERENT POSITIONS REQUIRE DIFFERENT PILOT POSTURES

POSITION	PILOT POSTURE
Leader	Defend established clinics with review leakage; prioritise durability of adoption and continuity through the franchise.
Challenger	Test adoption and review improvement in matched competitive clusters; track whether service usefulness creates incremental HCP engagement.
Selective share	Concentrate on one wedge and one supply-supported cluster; expand only after a repeatable operating result.

Illustrative feasibility design: 12 pathway clinics and 12 comparable usual-care clinics, about 20 matured episodes each. This is an operating example, not a powered sample-size calculation. Randomise clinics where feasible; obtain ethics/privacy review appropriate to the design.



DECISION GATES AND CAPACITY

ALLOCATE CAPACITY TO READINESS AND PROOF

The same opportunity is being shown to competing brand teams. Urgency comes from the time needed to train clinics, establish a trusted routine and produce evidence. It must not be manufactured through invented exclusivity or unavailable slots.

GATE	ILLUSTRATIVE THRESHOLD	DECISION
Launch	All clinics have approved content, consent, tested contact/fallback routes and named coverage.	No activation until every hard safety and governance condition is met.
Day 45 adoption	At least 80% of pathway clinics have enrolled eligible patients and completed the operating checks; burden remains acceptable.	Repair adoption or capacity before expanding.
Day 90 primary result	At least a 15-percentage-point improvement in day-28 closed-review rate versus the prespecified comparator, with denominators and uncertainty reported.	Proceed only if the result is credible and safety/capacity gates also pass. This threshold is illustrative, not a clinical standard.
Safety and equity	No unresolved serious process failure; urgent routes work; patients without smartphones or home devices retain access.	Pause the affected workflow and correct failures irrespective of sales.
Commercial and economic signal	Directionally credible independent continuity/share movement and a viable cost per additional completed review.	If operating proof is strong but commercial data are immature, extend measurement; do not declare ROI.

HONEST ALLOCATION LOGIC

Allocate scarce training, medical review and clinic-support capacity by documented readiness and observed workload. Publish real cohort dates once teams and clinics are confirmed. Keep each participating company's commercial data isolated; no shared price, territory or competitor-plan exchange.

First mover means first to establish a useful, functioning clinic routine. It does not mean first to claim ownership of clinical decisions.

CLOSING DECISION



DEFEND THE DEFAULT OR CHANGE THE BASIS OF COMPETITION

Cilnidipine does not need another explanation of why BP matters. It needs a better connection between the clinician's choice, the patient's real experience and the next clinical decision.

IF THE BRAND IS	THE DECISION NOW	THE COMMITMENT
THE LEADER	Defend default status by making review completion part of the clinic's infrastructure.	Choose the first defendable clinic cluster and own the operating standard.
A CHALLENGER	Attack the unfinished work between prescription and review.	Prove a useful loop that changes what the clinician compares.
A SELECTIVE-SHARE BRAND	Capture one measurable gap before spreading resources.	Name the wedge, clinic density, local supply and response capacity.

THE DECISION PACKET

Select one posture. Name one geography and clinic cohort. Confirm one accountable medical/operations owner. Define one primary metric. Set the 90-day start window and the evidence required to continue.

If these choices are absent, the activity remains another campaign. If they are present, a brand can test whether useful clinic infrastructure earns a more defensible place in the molecule.

The opportunity exists across cilnidipine. Every major competitor can see it. Decide which workflow the brand will defend or capture before a competitor makes it routine.

Generic molecule-wide architecture. No market share, clinical outcome, Academy endorsement, exclusivity or deployment capacity is guaranteed. Current product materials and the pilot configuration require the approvals described in the governance section.

MARKET EVIDENCE AND GUIDELINE FOUNDATIONS

Sources checked 26 September 2026. Numbers in square brackets refer to this list. Public sources are distinct from a licensed national market audit. Links lead to the source used; archive the approved version before deployment.

[1] WHO 2025 India hypertension profile
India sheet; 2024 estimates for adults aged 30–79. Disease burden and control, not cilnidipine prescriptions.

[2] JB Pharma Q3 FY26 investor presentation
Slides numbered 14–15: company-reported IQVIA MAT Dec 2025 brand and franchise sales. Visual source tables checked.

[3] Alembic Q1 FY27 investor presentation
Slide 6, Rx-driven rankings; source IQVIA MAT Jun 2026. Cetanil rank 2, 6.9% as reported; preserve the defined universe.

[4] JB Pharma Annual Report 2024–25
Printed page 50: Cilacar covered-market rank/share, MAT Mar 2025. A dated company-reported leadership proxy.

[5] NPPA retail-price computation file 4335
2025 compilation; file 4335 uses April 2024 data for cilnidipine/telmisartan/chlorthalidone 10/40/12.5 mg. Own count: 30 pack rows, 28 distinct brand labels; not a current national brand census.

[6] Torrent Q4 FY26 results release
Reports consolidation of JB acquisition effects from 21 January 2026. Used to distinguish brands from independent parent groups.

[7] RECORD Indian hypertension registry interim analysis
Five-centre observational registry, n=2,000. Supplementary Table I gives historical initial-diagnosis prescriptions in pre-existing hypertension; not current national Rx share.

[8] ESC 2024 elevated BP and hypertension guideline
Official guideline portal, including 2025 corrigendum. Class-based treatment, measurement, review and individualisation; no universal cilnidipine preference.

CLINICAL EVIDENCE AND APPROVED-LABEL SOURCES

[9] NICE NG136 recommendations
Diagnosis/HBPM, postural hypotension, treatment review and severe-BP referral. Diagnostic thresholds and treatment targets are distinct.

[10] WHO pharmacological hypertension guideline
2021 adult non-pregnant guidance; monthly follow-up after initiation/change and 3–6-month follow-up when controlled are conditional recommendations.

[11] Indian Society of Hypertension consensus guideline 2025
Hypertension Journal 11(4), doi:10.61081/htnj/25v11i401. Indian consensus context, measurement and follow-up. Its broader molecule claims are assessed against primary trials and the label.

[12] ESH home BP monitoring position paper 2021
Methodology, validated equipment and structured measurement. The treating clinic sets the actual patient schedule and interpretation.

[13] Torrent Torcilin full Indian prescribing information
Revised February 2026; monotherapy 5/10/20 mg. Indication, adverse effects, contraindications, reproductive cautions and interactions. One product PI is not a universal label.

[14] JB Cilacar T 20/40 mg Indian prescribing information
Revised February 2025. Combination-specific safety example; the deployed formulation's current PI must be checked.

[15] Randomised open-label cilnidipine versus amlodipine study
Indian study, 100 adults, 12 weeks. Comparable BP reductions and fewer reported edema/palpitations; limited design and no hard-outcome inference.

[16] Fujita et al CARTER trial 2007
Kidney International 72:1543–1549; n=339 on RAS inhibition, one year, open-label randomised comparison. Proteinuria is a surrogate endpoint.

EVIDENCE LIMITS AND GOVERNANCE SOURCES

[17] Ando et al SAKURA trial 2013
n=365 with type 2 diabetes and microalbuminuria on RAS inhibition; no greater albuminuria benefit versus amlodipine over 12 months.

[18] Shetty et al amlodipine-edema switch study 2013
Prospective 27-patient, four-week switch series. Selected population without randomised comparator; no universal edema-resolution promise.

[19] KDIGO CKD guideline 2024
Current published CKD framework at review; a focused update is underway. Supports indicated RAS blockade and kidney-protective care, not cilnidipine renal-superiority claims.

[20] UCPMP 2024 as updated 1 September 2025
Official code: approved-use promotion, fair substantiated claims, HCP interactions and education governance. Check for later amendments at deployment.

[21] MeitY DPDP Rules 2025 and enforcement timeline
Official rules, commencement documents and corrigendum. Implementation is phased; assess applicable requirements for the actual deployment date and design.

[22] Indian Pharmacopoeia Commission PvPI handbook
Reporting pathways for suspected adverse events/reactions. PV reporting complements urgent clinical care; it is not an emergency response channel.

[23] American Heart Association severe BP safety guidance
Patient safety foundation for very high readings and symptoms. Indian deployment must use the locally verified emergency route rather than the US telephone number.

How to read the evidence : Guidelines inform responsible clinical workflow. Product PI governs approved use. Trials support only their populations, comparisons and endpoints. Company disclosures and NPPA tables are dated market proxies. Commercial leakage, service advantage and pilot thresholds in this note are strategic hypotheses until measured.

STRATEGIC OPPORTUNITY & CTA

control and tolerability claims, or become the brand that helps clinics turn every appropriate prescription into a reliable, reviewed, and continuous care pathway?

Cilnidipine doesn't need another molecule-reminder campaign. It needs a brand that owns the measurement-to-review connection -helping clinics bring together reliable BP readings, tolerability concerns, and the next clinical decision.

Old rule: Win the prescription.
New rule: Own the review that makes the prescription assessable.

EMAIL:
Amit@inditech.co.in

WEBSITE:
Www.inditech.co.in

The next winning brand will become the clinic's BP-control and continuity partner - from the first measurement and early-use check to the first documented review and safe re-entry after a gap.

The opportunity is to make completed clinical reviews - not repeated brand reminders - the new basis of competition.

Next Steps

If you would like to explore how these ideas can be adapted to your brand strategy, we would be happy to discuss them further.

Get in touch with our team to schedule a 30-minute Cilnidipine Review Diagnostic and identify your brand's market posture, highest-value workflow gap, priority clinic cluster, and a focused 90-day pilot.

INDITECH HEALTH SOLUTIONS

PUBLICATION NO. 2026 09 111